

6th International Conference and Expo on Immunology

October 24-26, 2016 Chicago, USA

Differential expression of granzyme A and B in individuals with filarial infections

Alexander Kwarteng^{1,3}, Alex Debrah^{2,3}, Achim Hoerauf¹ and Sabine Specht¹¹University Hospital Bonn, Germany²Kwame Nkrumah University of Science and Technology, Ghana³Kumasi Centre for Collaborative Research in Tropical Medicine, Ghana

Granzyme A and B have been shown to play crucial role in *Litomosoides sigmodontis* infection, however, their importance in human filariasis remains to be fully characterized. To determine the expression pattern of human granzyme A and B in *W. bancrofti*-infected individuals as well as endemic normals, FACS intracellular staining was performed and measured with flow cytometer. The frequency of CD4⁺ T and CD8⁺ T cells expressing GZMB was significantly higher in *W. bancrofti*-infected compared to EN. To further establish whether CD4⁺ T and CD8⁺ T cells expressing GZMB are infection status depend, group-wise comparisons were performed. Interestingly, increased frequencies of CD4⁺GZMB⁺ and CD8⁺GZMB⁺ expressing T-cells were observed in the MF+ population compared to MF- and EN. In contrast, when compared to EN, there were no differences in the frequencies of CD4⁺GZMA⁺-expressing T in *W. bancrofti* infected group; however, upon further analysis, GZMA⁺-producing CD4⁺ and CD8⁺ T cells were significantly increased in MF-, but were highly expressed in MF+ and EN. In general the proportion of CD8⁺GZMA⁺ expressing T-cells was almost 2 fold of CD4⁺GZMA⁺ expressing T-cells. The results demonstrate that individuals with patent infection present increased frequencies of GZMB-producing CD4⁺ and CD8⁺ T cells, which may support MF survival or facilitate peripheral circulation given that GZMB has a unique degradation of extracellular matrix, whereas up-regulation of GZMA levels in MF- individuals and EN could promote protection against filarial.

senkwarteng@yahoo.co.uk

HIV cure and latency: New targets and therapeutics

Rachel Pasos

Triton College, USA

HIV has been a challenge to the scientific community in many areas such as HIV cure and Latency, HIV Immune enhancement and activation, concerning a vaccine, also adding to its complication, NeuroAIDS a disorder which has affected 50 percent of adults with AIDS according to NIH Aids.gov. There is also the challenge of HIV medication adverse effect and those who are on lifelong therapeutics, in which these challenges has been overcome by new targets and therapeutics that are sure to deliver. Presentation: HIV cell entry and NMDA receptors involvement, Germ line mutation, Endogenous Retrovirus. The identification of several HIV microorganisms. Immune Repertoire challenges.

r4ch3lp92@gmail.com